

Amendments to the Specification:

On pages 4, please amend the paragraph starting on line 4 as follows:

- Said object according to the invention is accomplished by the present invention by means of a kit comprising *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) (*cis*-oxoplatin, oxoplatin), particularly salts thereof, and, physically separated therefrom, a base material of a pharmaceutical agent selected from the group comprising a tablet, a capsule, a coated tablet, a suppository, an ointment, a cream, a solution for infusion and/or injection, and optionally information relating to contacting or combining the contents of the kit, said base materials being selected in such a way that, following contacting or combining the *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) with the base material,
- the capsule comprises oxoplatin : silicon dioxide : mannitol or magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
 - the tablet comprises *cis*-oxoplatin : lactose : corn starch : poly(O-carboxymethyl)starch sodium salt : calcium hydrogen phosphate $\times 2\text{H}_2\text{O}$: cellulose powder : magnesium stearate at a ratio of 10 to 500 : 20 to 150 : 1 to 10 : 1 to 10 : 1 to 10 : 0.1 to 7; or
 - the tablet alternatively comprises *cis*-oxoplatin : silicon dioxide : magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
 - the cream comprises *cis*-oxoplatin : benzyl alcohol : cetyl stearyl alcohol : Macrogol stearate 1000 : isopropyl palmitate : glycerol : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 0.1 to 7 : 1 to 10 : 0.1 to 7 : 0.1 to 7 : 0.2 to 8 : 0.2 to 8 : 20 to 60;
 - the ointment comprises *cis*-oxoplatin : propylene glycol : Macrogol stearate 1000 : cetyl stearyl alcohol : ~~vaseline~~ VASELINE petrolatum at a ratio of 2 to 20 : 5 to 40 : 0.1 to 7 : 1 to 10 : 25 to 400;
 - the gel comprises *cis*-oxoplatin : hydroxyethylcellulose : chlorocresol : sodium hydroxide : sodium hydrogen phosphate dihydrate : water at a ratio of 2 to 20 : 100 to 600 : 5 to 40 : 0.1 to 7 : 20 to 60 : 3,000 to 50,000;
 - the suppository comprises *cis*-oxoplatin : silicon dioxide : hardened fat at a ratio of 0.1 to 10 : 0.1 to 10 : 30 to 300; or

- the suppository alternatively comprises *cis*-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : highly dispersed silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 700 to 4,000 : 200 to 600 : 10 to 1000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 10; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose \times 1H₂O : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 1,000 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose \times 1H₂O : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 1,000 : 1,500 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7;
- the solution for injection or infusion comprises *cis*-oxoplatin : benzyl alcohol : Polysorbate 80 : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 1 to 10 : 0.1 to 7 : 100 to 800 : 100 to 400; or
- the solution for injection or infusion alternatively comprises *cis*-oxoplatin : mannitol : water at a ratio of 0.1 to 7 : 5 to 40 : 1 to 10. --

On page 12, please amend the paragraph starting on line 4 as follows:

-- Furthermore, a kit is preferred wherein the capsule, following contacting of *cis*-oxoplatin and base material, comprises 50 mg of silicon dioxide, 50 mg of mannitol or 50 mg of magnesium stearate and 50 mg of oxoplatin, or, alternatively, 50 mg of *cis*-oxoplatin, 39.5 mg of lactose or 39 mg, 2.5 mg or 2 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate \times 2H₂O, 2.5 mg of cellulose powder, and 0.5 mg of magnesium stearate, or, alternatively, *cis*-oxoplatin, 50 mg of silicon dioxide and 50 mg of magnesium stearate. In another preferred kit, the cream, following contacting of *cis*-oxoplatin and base material, comprises 50 mg of *cis*-oxoplatin, 20 mg of benzyl alcohol, 100 mg of cetyl stearyl alcohol, 25 mg of Macrogol stearate 1000, 20 mg of isopropyl palmitate, 40 mg of glycerol, 50 mg of sorbitol, and 205 mg of water. Furthermore, a kit is preferred wherein the ointment, following contacting of *cis*-oxoplatin and base material, comprises 50 mg of *cis*-oxoplatin, 120 mg of propylene glycol, 5.5 mg of Macrogol

stearate 1000, 22 mg of cetyl stearyl alcohol, and 851.5 mg of ~~vaseline~~ VASELINE petrolatum.--

On page 18, please amend the paragraph starting on line 18 as follows:

-- For example, the ointments according to the invention are constituted of a lipophilic base, such as paraffin oil, ~~vaseline~~ VASELINE petrolatum and wool fat, and may include about 10% powder such as zinc oxide, titanium oxide, starch or another powder mixture. In hydrophobic ointments in the meaning of the invention, the outer phase is lipophilic, i.e., these ointments represent an emulsion of water in fat. --

On page 22, please amend the paragraph starting on line 31 as follows:

-- When using the chemotherapeutical agent in the form of an ointment, it is preferred to use an ointment which, in addition to *cis*-oxoplatin, includes white ~~vaseline~~ VASELINE petrolatum, cetyl stearyl alcohol, Macrogol stearate 1000, and propylene glycol.--

On page 23, please amend the paragraph starting on line 1 as follows:

--In a preferred embodiment of the invention the ointment includes the individual components *cis*-oxoplatin : propylene glycol : Macrogol stearate 1000 : cetyl stearyl alcohol : white ~~vaseline~~ VASELINE petrolatum at a ratio of 2 to 20 : 5 to 40 : 0.1 to 7 : 1 to 10 : 25 to 400, preferably at a ratio of 5 to 12 : 10 to 30 : 0.2 to 3 : 2 to 9 : 50 to 250, and more preferably at a ratio of 6 to 10 : 15 to 25 : 0.5 to 1.5 : 3 to 6 : 100 to 200, and especially at a ratio of 9.1 : 22 : 1 : 4 : 155. Accordingly, the ointment according to the invention may comprise e.g. 50 mg of *cis*-oxoplatin, 120 mg of propylene glycol, 5.5 mg of Macrogol stearate 1000, 22 mg of cetyl stearyl alcohol, and 851.5 mg of white ~~vaseline~~ VASELINE petrolatum.--

On page 27, please amend the paragraph starting on line 22 as follows:

-- Thus, the invention relates to a method for the production of a chemotherapeutical agent, i.e. a pharmaceutical agent, in which method *cis*-diammoniumdichloro-*trans*-

dihydroxoplatinum(IV) (*cis*-oxoplatin), and particularly the salts thereof, are contacted with a base material of a pharmaceutical agent selected from the group comprising a tablet, a capsule, a coated tablet, a suppository, an ointment, a cream, a solution for infusion and/or injection, said base materials being selected in such a way that, following contacting of *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) with the base material,

- the capsule comprises oxoplatin : silicon dioxide : mannitol or magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
- the tablet comprises *cis*-oxoplatin : lactose : corn starch : poly(O-carboxymethyl)starch sodium salt : calcium hydrogen phosphate $\times 2\text{H}_2\text{O}$: cellulose powder : magnesium stearate at a ratio of 10 to 500 : 20 to 150 : 1 to 10 : 1 to 10 : 1 to 10 : 1 to 10 : 0.1 to 7; or
- the tablet alternatively comprises *cis*-oxoplatin : silicon dioxide : magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
- the cream comprises *cis*-oxoplatin : benzyl alcohol : cetyl stearyl alcohol : Macrogol stearate 1000 : isopropyl palmitate : glycerol : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 0.1 to 7 : 1 to 10 : 0.1 to 7 : 0.1 to 7 : 0.2 to 8 : 0.2 to 8 : 20 to 60;
- the ointment comprises *cis*-oxoplatin : propylene glycol : Macrogol stearate 1000 : cetyl stearyl alcohol : ~~vaseline~~ VASELINE petrolatum at a ratio of 2 to 20 : 5 to 40 : 0.1 to 7 : 1 to 10 : 25 to 400;
- the gel comprises *cis*-oxoplatin : hydroxyethylcellulose : chloro-aerosol : sodium hydroxide : sodium hydrogen phosphate dihydrate : water at a ratio of 2 to 20 : 100 to 600 : 5 to 40 : 0.1 to 7 : 20 to 60 : 3,000 to 50,000;
- the suppository comprises *cis*-oxoplatin : silicon dioxide : hardened fat at a ratio of 0.1 to 10 : 0.1 to 10 : 30 to 300; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : highly dispersed silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 700 to 4,000 : 200 to 600 : 10 to 1000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 10; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose $\times 1\text{H}_2\text{O}$: corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate :

- silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 1,000 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose \times 1H₂O : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 1,000 : 1,500 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7:
 - the solution for injection or infusion comprises *cis*-oxoplatin : benzyl alcohol : Polysorbate 80 : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 1 to 10 : 0.1 to 7 : 100 to 800 : 100 to 400; or
 - the solution for injection or infusion alternatively comprises *cis*-oxoplatin : mannitol : water at a ratio of 0.1 to 7 : 5 to 40 : 1 to 10.--

On page 44, please amend the paragraph starting on line 23 as follows:

-- In a first test series, tablets, ointments and infusion solutions were tested on various tumor rats developing both internal and external tumors. The other drugs according to the invention were tested in additional, subsequent test series. Following combining of *cis*-oxoplatin and base material, the tablet included 50 mg of *cis*-oxoplatin, 39.5 mg of lactose, 2.5 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate \times 2H₂O, 2.5 mg of cellulose powder, and 0.5 mg of magnesium stearate. Following contacting *cis*-oxoplatin with base material, the ointment included 50 mg of *cis*-oxoplatin, 120 mg of propylene glycol, 5.5 mg of Macrogol stearate 1000, 22 mg of cetyl stearyl alcohol, and 851.5 mg of ~~vaseline~~ VASELINE petrolatum. In a preparation of 5 mg/ml solution, the infusion solution included 5 mg of *cis*-oxoplatin, 9 mg of benzyl alcohol, 2 mg of Polysorbate 80, 650 mg of 70% sorbitol solution, and 500 mg of water.--